Our initial focus lies in the development of therapies for a range of refractory solid tumors including pancreatic ductal adenocarcinoma, glioblastoma and metastatic colorectal cancer. Preclinical study results from our programs suggest that our development candidates are highly efficacious after systemic delivery in a wide range of tumours and our lead programmes are poised to enter clinical development.

The development candidates are based on a propriety genetically modified Lister strain Vaccinia virus. Gene deletions enhance tumor specific and induction of anti-tumor responses. Addition of payloads act to enhance viral spread within and between tumours, reduce early viral clearance and remodel the immunosuppressive micro tumor environment to promote robust anti-tumor immunity. Our development candidates can act as monotherapies to deliver therapeutic effect, however efficacy is significantly enhanced in combination with existing immunotherapies.